Accuray CyberKnife widely used for treating extracranial tumors
Accuray Incorporated is touting utilization data for its CyberKnife system that indicates that 100 percent of CyberKnife centers in the United States are treating extracranial tumors. Specifically, treatments of lung and prostate cancers are on the rise at these facilities.
The latest data show that approximately 90 percent of CyberKnife centers in the United States now treat lung tumors with radiosurgery. The number of lung patients treated worldwide rose by a dramatic 30 percent from first to second quarter of fiscal 2007. Similarly, there was a 30 percent increase in the number of prostate patients treated during that same time frame. Accuray said that this demonstrates that an increasing number of centers are using the CyberKnife system to treat these indications and an increasing number of their patients are receiving these treatments.
Most radiosurgery traditionally has been used for the treatment of intracranial tumors, yet the CyberKnife system has extended radiosurgical applications to include the treatment of tumors anywhere in the body.
The latest data show that approximately 90 percent of CyberKnife centers in the United States now treat lung tumors with radiosurgery. The number of lung patients treated worldwide rose by a dramatic 30 percent from first to second quarter of fiscal 2007. Similarly, there was a 30 percent increase in the number of prostate patients treated during that same time frame. Accuray said that this demonstrates that an increasing number of centers are using the CyberKnife system to treat these indications and an increasing number of their patients are receiving these treatments.
Most radiosurgery traditionally has been used for the treatment of intracranial tumors, yet the CyberKnife system has extended radiosurgical applications to include the treatment of tumors anywhere in the body.